Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome.
about
Unraveling the Pathogenesis of MDS: The NLRP3 Inflammasome and Pyroptosis Drive the MDS PhenotypeReport on the use of non-clinical studies in the regulatory evaluation of oncology drugsClinical potential of pacritinib in the treatment of myelofibrosisIRAK signalling in cancerRole of microRNA-146a in normal and malignant hematopoietic stem cell functionIL-1 Receptor-Associated Kinase Signaling and Its Role in Inflammation, Cancer Progression, and Therapy ResistanceDeconstructing innate immune signaling in myelodysplastic syndromesDeregulation of innate immune and inflammatory signaling in myelodysplastic syndromesThe Role of Toll-Like Receptors in Hematopoietic MalignanciesUbiquitination of hnRNPA1 by TRAF6 links chronic innate immune signaling with myelodysplasia.Errant innate immune signaling in del(5q) MDS.An MDS xenograft model utilizing a patient-derived cell line.Interleukin 1 receptor-associated kinase 1 (IRAK1) mutation is a common, essential driver for Kaposi sarcoma herpesvirus lymphoma.Myeloid malignancies with chromosome 5q deletions acquire a dependency on an intrachromosomal NF-κB gene networkInhibition of IRAK1/4 sensitizes T cell acute lymphoblastic leukemia to chemotherapies.IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cellsLoss of Tifab, a del(5q) MDS gene, alters hematopoiesis through derepression of Toll-like receptor-TRAF6 signalingSLC7A5 act as a potential leukemic transformation target gene in myelodysplastic syndrome.Regulation of stress-induced hematopoiesisBiology of the bone marrow microenvironment and myelodysplastic syndromes.IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel.Targeting IRAK1 in T-cell acute lymphoblastic leukemiaDiagnostic and prognostic roles of IRAK1 in hepatocellular carcinoma tissues: an analysis of immunohistochemistry and RNA-sequencing data from the cancer genome atlasRps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9Lenalidomide Stabilizes the Erythropoietin Receptor by Inhibiting the E3 Ubiquitin Ligase RNF41.Targeting interleukin-1 receptor-associated kinase 1 for human hepatocellular carcinoma.Induction of myelodysplasia by myeloid-derived suppressor cells.Stem cell origin of myelodysplastic syndromes.IRAK1 is a novel DEK transcriptional target and is essential for head and neck cancer cell survival.The inflammatory microenvironment in MDS.Toll-like receptor signaling in hematopoietic homeostasis and the pathogenesis of hematologic diseases.Pacritinib: a new agent for the management of myelofibrosis?β-Catenin Is a Candidate Therapeutic Target for Myeloid Neoplasms with del(5q).Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML.Stem and progenitor cell alterations in myelodysplastic syndromes.The oral iron chelator deferasirox inhibits NF-κB mediated gene expression without impacting on proximal activation: implications for myelodysplasia and aplastic anaemia.Constitutive IRAK4 Activation Underlies Poor Prognosis and Chemoresistance in Pancreatic Ductal Adenocarcinoma.Inflammation: a key regulator of hematopoietic stem cell fate in health and disease.The study of homology between tumor progression genes and members of retroviridae as a tool to predict target-directed therapy failure.Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor.
P2860
Q26744481-D37906C8-3033-45F3-8A6A-C05BE3B517FAQ26766039-737C1F28-978B-4F0D-820B-47D4853303C8Q26796450-A8B4BEE8-8895-4A7A-8C53-84A068009A4BQ26863735-84A8B186-FCA2-426A-8CD1-FF2FAE819BAAQ26864607-8694E727-CB29-4E3A-A186-C5EF0BBB1FA6Q26866390-8CE3C9EE-FC95-4504-B29E-A5002352747AQ26991974-D91BC89A-214B-4C70-A95D-871C75111BB4Q27015288-E9141DFB-4756-4E8A-AB31-B6FA8CF57CEAQ28077740-DE17373B-87CE-48BF-AD53-4EA407EC5D71Q33652652-3C9BC149-D686-4BAB-8A1F-4E3D8857C95BQ33987039-0800AFF6-43B2-472A-B80C-0DCDFEB29198Q34433095-6B97C645-69DC-4F9F-92A5-6108384B1722Q34480968-4E10402E-0579-4E0C-824D-351A445BCD3DQ34540749-D84B851B-0A2F-48A5-9280-109C24E60D81Q35183900-586F2CFC-E575-4B34-80B1-DEAA7F89A4FBQ35607293-0C53E7EC-58C9-4124-B731-EEF1FCC6C51AQ35803662-C3FB0D2A-E4CE-4DD2-AEF3-D9EC1BF9BD8BQ35866423-79A82C57-CC4D-4AD3-B538-DF7B22B5EFC7Q36069153-E1EFBD71-324B-43B6-924F-6A29E1516D17Q36201068-66CF02A8-E89E-4938-A23F-65CD1D7BD28DQ36266768-39CF1FB5-9926-4E3A-8974-FC19F984ECC3Q36326296-9890602C-5BD6-44FD-9761-2C72E1532E0BQ36327564-DAE06B00-5695-4375-AD05-5FF8A386A843Q36909178-0C2CF2EF-16F6-4577-AF6D-5578607DB093Q37014078-C9C96DDF-70CA-4BB7-9FEB-44F1C8FB472FQ37251454-338B7663-4F01-47D7-B8E5-0EDBF8691F0BQ37259216-B79AF3D6-6E1E-4415-AA19-F06D604C15CDQ38171230-7A033800-253C-4718-A33A-2314F74986F3Q38295578-FC0FCA33-125C-45AE-B392-79AFAF99DCCAQ38348119-A388B6B1-6AC8-4DE3-96A5-E9D7A1B30E68Q38571471-D4B59CC6-EC50-48CB-92C8-22C15DEE19D9Q38590232-9352D925-F345-4F1A-B50C-2E1FA2AF1222Q38727081-C8592BD0-39E8-4247-B0F6-6C6ECCBE3036Q38747542-6499E980-01F6-4FA7-B868-A6C832797496Q38761791-615DBCC3-2267-43FB-B832-0AD8A31FAAB7Q38951695-3DD1E87D-1622-406E-9E7D-43931DAE3456Q39323428-D5751B09-1532-4B6E-AC2C-C8D343FA1037Q40066012-8FB566F2-3930-4ABB-B6B7-95B94E9093F1Q40151542-9579B1F7-FCAC-4612-A3F8-D870A96A4F77Q41448224-3C516F2E-D57A-4713-B039-0D25AE85A9AC
P2860
Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome.
@en
Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome.
@nl
type
label
Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome.
@en
Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome.
@nl
prefLabel
Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome.
@en
Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome.
@nl
P2093
P2860
P1433
P1476
Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome.
@en
P2093
Andres Jerez
Carmela Rigolino
Craig Thomas
Daniel T Starczynowski
Esther N Oliva
Garrett W Rhyasen
James C Mulloy
Jaroslaw P Maciejewski
Jonathan Keller
P2860
P304
P356
10.1016/J.CCR.2013.05.006
P577
2013-07-01T00:00:00Z